SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Kristin C. Carlsson Petri, Lisbeth V. Jacobsen, David J. Klein, Comparable Liraglutide Pharmacokinetics in Pediatric and Adult Populations with Type 2 Diabetes: A Population Pharmacokinetic Analysis, Clinical Pharmacokinetics, 2015,

    CrossRef

  2. 2
    Chuanpu Hu, Omoniyi Adedokun, Kaori Ito, Sangeeta Raje, Ming Lu, Confirmatory population pharmacokinetic analysis for bapineuzumab phase 3 studies in patients with mild to moderate Alzheimer's disease, The Journal of Clinical Pharmacology, 2015, 55, 2
  3. 3
    Matthew M. Hutmacher, Kenneth G. Kowalski, Covariate selection in pharmacometric analyses: a review of methods, British Journal of Clinical Pharmacology, 2015, 79, 1
  4. 4
    S.H. Ingwersen, K.C. Petri, N. Tandon, K.-H. Yoon, L. Chen, J. Vora, W. Yang, Liraglutide pharmacokinetics and dose-exposure response in Asian subjects with Type 2 diabetes from China, India and South Korea, Diabetes Research and Clinical Practice, 2015,

    CrossRef

  5. 5
    Andrew T. Chow, Justin C. Earp, Manish Gupta, William Hanley, Chuanpu Hu, Diane D. Wang, Stefan Zajic, Min Zhu, Utility of population pharmacokinetic modeling in the assessment of therapeutic protein-drug interactions, The Journal of Clinical Pharmacology, 2014, 54, 5
  6. 6
    Matthew M. Riggs, Alexander Staab, Leo Seman, Thomas R. MacGregor, Timothy T. Bergsma, Marc R. Gastonguay, Sreeraj Macha, Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes, The Journal of Clinical Pharmacology, 2013, 53, 10
  7. 7
    Jane R. Kenny, Maggie M. Liu, Andrew T. Chow, Justin C. Earp, Raymond Evers, J. Greg Slatter, Diane D. Wang, Lei Zhang, Honghui Zhou, Therapeutic Protein Drug–Drug Interactions: Navigating the Knowledge Gaps–Highlights from the 2012 AAPS NBC Roundtable and IQ Consortium/FDA Workshop, The AAPS Journal, 2013, 15, 4, 933

    CrossRef

  8. 8
    Bernd Meibohm, Honghui Zhou, Characterizing the Impact of Renal Impairment on the Clinical Pharmacology of Biologics, The Journal of Clinical Pharmacology, 2012, 52, S1
  9. 9
    Min Zhu, Yu-Nien (Tom) Sun, Logistic Considerations in Study Design for Biologic Drug–Drug Interaction Assessments, Pharmaceutical Sciences Encyclopedia,
  10. 10
    Chuanpu Hu, Honghui Zhou, Statistical Considerations in Assessing Drug–Drug Interactions for Therapeutic Biologics, Pharmaceutical Sciences Encyclopedia,